HIGHLY EFFECTIVE ORIGINAL PHYTOPRODUCT GINDARIN (REVIEW)

Download full text PDF
Issue: 
2
Year: 
2017

G.F. Sidelnikova Research Scientist, Department of Experimental and Clinical Pharmacology, Center of Medicine, All-Russian Scientific Research Institute of Medicinal and Aromatic Plants (Moscow) E-mail: gal.fil@mail.ru V.V. Karabaeva Senior Research Scientist, Department of Experimental and Clinical Pharmacology, Center of Medicine, All-Russian Scientific Research Institute of Medicinal and Aromatic Plants (Moscow) V.K. Kolkhir Dr.Sc. (Med.), Chief Research Scientist, Department of Experimental and Clinical Pharmacology, All-Russian Scientific Research Institute of Medicinal and Aromatic Plants (Moscow) I.V. Voskoboynikova Ph.D. (Pharm.), Leading Research Scientist, Department of Experimental and Clinical Pharmacology, All-Russian Scientific Research Institute of Medicinal and Aromatic Plants (Moscow) E.V. Ferubko Ph.D. (Med.), Head of Department of Experimental and Clinical Pharmacology, All-Russian Scientific Research Institute of Medicinal and Aromatic Plants (Moscow) М.А. Javakhian Ph.D. (Pharm.), Head of Department of Pharmaceutical Technology, All-Russian Scientific Research Institute of Medicinal and Aromatic Plants (Moscow) E.N. Kurmanova Research Scientist, Department of Experimental and Clinical Pharmacology, All-Russian Scientific Research Institute of Medicinal and Aromatic Plants (Moscow)

The neurotic disorders are widespread in different age groups of the population both in our country and abroad. At present, the neurotic disorders are actively treated in the medical practice by extracts of therapeutic plants (valerian, motherwort, peony, etc.), as well as by combined and multi-component phytoproducts (Phyto Novo-Sed, Novo-Passit, etc.). A large contribution to the investigation and development of phytoproducts in our country has been made by scientists and staff of the National Institute of Therapeutic and Aromatic Plants (VILAR). More than 120 herbal therapeutic products have been developed in the Institute laboratories during the peri-od of its activity. Among them, an original therapeutic herbal product Gindarin, which shows sedative properties, was developed and studied. Gindarin is a hydrochloride form of alkaloid 1-tetrahydropalmatine isolated from Stephania glabra L. roots. Gindarin demonstrates moderate tranquilizing effect and alleviates anxiety and irritability in patients with functional disorders of the central nervous system. It is also characterized by hypotensive properties and adrenolytiс effect on autonomous nervous system. Gindarin preclinical safety studies confirmed the drug low toxicity without the teratogenic, mutagenic or sensitizing properties. Gindarin clinical studies were performed in 1960-1962, and later in 1966-1968 in more than 300 patients in 7 specialized re-search & clinical centers. The drug was used as an soporific, sedative, anti-seizure agent, and clinical studies have shown its high ther-apeutic efficacy. Despite the inadequate choice of the reference products (comparator drugs included Meprobamate, Trioxazin, Elenium, Seduxen (!), Gindarin was noted to show significant psychotropic activity and possibility of use in a wide range of neurotic disorders, independ-ent of their nosologic group. Gindarin film-coated tablets 0.05 g were approved for use in medical practice as sedative in 1977. The highest single dose is 0.1 g. Taking into account the thorough previous studies, renewal of the product registration in Russia will not need much additional studies. VILAR scientists believe that Gindarin has both unique history and promising future.

Keywords: 
Key words: gindarin
phytoproduct
neurotic disorders
clinical studies.

It appears your Web browser is not configured to display PDF files. Download adobe Acrobat или click here to download the PDF file.